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Abstract
Background: In April 2011, the World Health Organization (WHO) published a list of ‘‘priority medicines’’ for maternal and
child health based on 1) the global burden of disease and 2) evidence of efficacy and safety. The objective of this study was
to examine the occurrence of these priority medicines on national essential medicines lists.
Methods and Findings: All essential medicines lists published since 1999 were selected from the WHO website collection.
The most-up-to date list for each country was then selected, resulting in 89 unique country lists. Each list was evaluated for
inclusion of medicines (chemical entity, concentration, and dosage form) on the Priority Medicines List. There was global
variation in the listing of the Priority Medicines. The most frequently listed medicine was paracetamol, on 94% (84/89) of
lists. Sodium chloride, gentamicin and oral rehydration solution were on 93% (83/89) of lists. The least frequently listed
medicine was the children’s antimalarial rectal artesunate, on 8% of lists (7/89); artesunate injection was on 16% (14/89) of
lists. Pediatric artemisinin combination therapy, as dispersible tablets or flexible oral solid dosage form, appeared on 36%
(32/89) of lists. Procaine benzylpenicillin, for treatment of pediatric pneumonia and neonatal sepsis, was on 50% (45/89) of
the lists. Zinc, for treatment of diarrhoea in children, was included on only 15% (13/89) of lists. For prevention and treatment
of postpartum hemorrhage in women, oxytocin was more prevalent on the lists than misoprostol; they were included on 55
(62%) and 31 (35%) of lists, respectively. Cefixime, for treatment of uncomplicated anogenital gonococcal infection in
woman was on 26% (23/89) of lists. Magnesium sulfate injection for treatment of severe pre-eclampsia and eclampsia was
on 50% (45/89) of the lists.
Conclusions: The findings suggest that countries need to urgently amend their lists to provide all priority medicines as part
of the efforts to improve maternal and child health.
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Introduction
Improving maternal and child health is a global priority. In
2011, an estimated 7.6 million children under the age of five died
[1]. Almost 358,000 women – most of them in low income
countries – died from complications of pregnancy and childbirth
[1]. According to the UN Commission on Life-Saving Commod-
ities for Women and Children, many of these deaths are due to
conditions such as infections, haemorrhage, pneumonia, and
malaria that can be prevented or treated by affordable medicines
(http://www.who.int/reproductivehealth/news/un_commission/
en/index.html).
In April 2011, WHO published a list of ‘priority medicines’ for
maternal and child health to support countries making choices
about medicines for treating women and children [2]. These
medicines were selected based on 1) the global burden of disease
and 2) the evidence of efficacy and safety for preventing or treating
maternal, newborn, and child mortality and morbidity. The
priority medicines are a subset of the WHO Model Essential
Medicines List. Priority medicines for maternal health are those
for management of post-partum haemorrhage, severe pre-
eclampsia and eclampsia, maternal sepsis, sexually transmitted
infections (chlamydia, gonococcal infections, and syphilis), preterm
birth, and maternal HIV/AIDS and malaria. For children, the list
includes medicines for treating pneumonia, diarrhoea, malaria,
neonatal sepsis, HIV, vitamin A deficiency, and tuberculosis.
Medicines for pediatric palliative care, vitamin A deficiency, and
HIV/TB prophylaxis are also included, as well as medicines for
neonatal care.
Data from country surveys show that access to essential
medicines, particularly for children, is generally poor [3,4,5,6].
Reasons for the lack of essential medicines include fragile supply
systems, out-of-pocket payments which make the medicines
unaffordable, and poor quality products [7,8]. Essential medicines
should be manufactured according to quality standards, licensed
for use by regulatory authorities, on essential medicines lists, part
of national standard treatment guidelines, procured from the
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by health care professionals who know how to use them. National
essential medicines lists are a first step to ensuring access to
medicines as they can guide procurement, local licensing and
manufacturing, and the rational use of high quality essential
medicines [9]. National essential medicines lists also help to guide
allocation of limited resources and can be used as an advocacy tool
to promote the accessibility of essential medicines. Therefore,
national essential medicines lists are an indicator of the current
supply of medicines through the public sector.
In 2007, WHO found that 131 of 151 countries surveyed had
an essential medicines list.
The objective of this study was to examine the inclusion of the
priority medicines for maternal and child health on national
essential medicines lists.
Methods
WHO maintains a publically available collection of the national
essential medicines lists that have been submitted to WHO by
member states at: http://www.who.int/selection_medicines/
country_lists/en/index.html. This contained lists from 101
countries at the time this study was conducted. For this study,
all essential medicines lists published since 1999, 10 years prior to
the Priority Medicines list, were selected from the website. The
most-up-to date list for each country was then selected, resulting in
89 unique country lists for analysis. Each EML was evaluated for
concordance with the medicines listed in the WHO List of Priority
Medicines for Mothers and Children 2011 [10] by AY and
Monique Renevier (noted in acknowledgements). Any discrepan-
cies were adjudicated by the other authors (SH or LB). The
Priority Medicines list includes 26 individual chemical entities in
41 dosage forms and strengths.
We excluded from analysis medicines for HIV for children as
these were not fully specified on the Priority List. Many countries
may have separate programs for supply of antiretrovirals, so these
medicines are not specified as part of a national essential medicines
list. We also excluded the ‘missing’ medicines on the Priority List
(formulations for treatment of paediatric TB, HIV/TB co-
treatment, chlorhexidine for umbilical cord care, vitamin K for
haemorrhagic disease of the newborn, and caffeine citrate for
apnoea) as these formulations either do not exist, or have not yet
been fully commercialized. The priority medicines listed for
pediatric tuberculosis allow for combined treatments of ethambu-
tol, rifampicin, isoniazid, and pyrazinamide. The preferable fixed
dose combination of TB medicines is not available. A fixed dose
combination of isoniazid and co-trimoxazole is listed for pediatric
HIV/TB prophylaxis, but also does not yet exist [11]. Therefore,
we assessed the concordance of 28 chemical entities in 41 dosage
forms and strengths (see Table 1) with national essential medicines
lists.
We compared specification of the drug as the International
Nonproprietary Name (INN), dosage form, and strength. For
medications listed in the Priority Medicines list as ‘variable oral
solid dosage forms’, any dosage forms that met the definition in the
WHO Model List of Essential Medicines for Children 2010 were
considered to be concordant. As the ‘scored dispersible’ 20 mg
zinc tablet recommended on the Priority Medicines List is not
widely available, we checked for zinc 20 mg tablets. Additionally,
any artemisinin combination therapy (ACT) for malaria treatment
as defined by WHO Guidelines for the Treatment of Malaria [12]
was considered concordant, noting, however, that ideally, ACT for
children would be in the appropriate flexible oral solid dosage
forms (such as dispersible tablets).
Partial matches where the listed medicines were identical in
INN and form (or the form was completely interchangeable such
as tablet and capsule), but had a different strength or vial size, were
discussed by two coders to decide if the match was sufficient.
Medicines that were listed by INN only were not considered as
fully concordant with the medicines on the Priority Medicines List.
Analysis
We calculated the percentage of countries globally and by
WHO region that included each priority medicine on its national
medicines list. The most common deficiencies, as well as common
inappropriate dosage forms were identified.
Results
As shown in Figure 1, there was considerable global variation in
the listing of Priority Medicines for Mothers and Children on
national essential medicines lists. Data for individual country lists
can be found in the Supplemental file (Table S1). The most
frequently listed medicine was paracetamol (variable flexible oral
dosage form) which was on 94% (84/89) of lists. Sodium chloride,
gentamicin, and oral rehydration salts (ORS) were also frequently
listed and appeared on 93% (83/89) of lists.
Six medicines were listed on fewer than 50% of the lists. The
least frequently listed medicine was the antimalarial rectal
artesunate which was on 8% of lists (7/89); artesunate injection
was on 16% (14/89) of lists. Appropriate artemisinin combination
therapy, as dispersible tablets or flexible oral solid dosage form,
appeared on 36% (32/89) of lists. Procaine benzylpenicillin, for
treatment of pediatric pneumonia and neonatal sepsis, was on
50% (45/89) of the lists. Zinc, for treatment of diarrhoea in
children, was included on only 15% (13/89) of lists.
For prevention and treatment of postpartum hemorrhage in
women, oxytocin was more prevalent on the lists than misoprostol;
included on 55 (62%) and 31 (35%) of lists, respectively. Cefixime,
for treatment of uncomplicated anogenital gonococcal infection in
woman was on 26% (23/89) of lists. Magnesium sulfate injection
for treatment of severe pre-eclampsia and eclampsia was on 50%
(45/89) of the lists.
Twenty-four of the national essential medicine lists were last
updated prior to 2007. There was one list from 1999; all others
prior to 2007 were from 2001 to 2007. The four priority medicines
most recently added to the WHO Model Essential Medicines List
were misoprostol, cefixime, nifedipine, and zinc, all added in 2006.
The more up to date lists were more likely to contain the four
medicines added in 2006 than the older lists (Table 2). One
exception is nifedipine which until 2005 had been listed on the
WHO Model Essential Medicines List as an antihypertensive.
Figure 2 shows that there is substantial regional variation in the
listing of medicines for mothers. Misoprostol was more likely to be
listed on country essential medicines lists in the WPRO region
than any other region.
There was even greater global variability in the listing of
selected medicines for children (Figure 3). The African continent
has the highest number of malaria cases and deaths, with 174000
cases and 596,000 deaths estimated in 2010. This is followed by
Southeast Asia with 28000 cases and 38000 deaths estimated in
2010 [13]. Thus, listing of the antimalarials is particularly
important for the AFRO and SEARO regions. As shown in
Figure 3, AFRO region countries were more likely to list
artemisinin combination therapy than artesunate in either
formulation, while the countries with EMLs in the SEARO region
were more likely to list artemisinin combination and artesunate
injection rather than artesunate rectal. The rectal form of
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in any region.
Countries with the highest incidence of malaria cases and deaths
also do not uniformly list the artesunate medicines. In 2010, 15
countries (12 of which are in the AFRO region) had more than
10,000 cases of malaria per 100,000 [13]. Of these 15 countries, 7
had an essential medicines list included in this study: Burundi,
Ghana, Maurtania, Senegal, Sudan, Yemen and The Solomon
Islands. In the AFRO region, Burundi, Ghana, Mauritania, and
Senegal listed artemisinin combination, while only Ghana listed
artesunate (both rectal and injection). In the EMRO region, both
Sudan and Yemen listed artemisinin combinations, Sudan listed
only artesunate rectal, and Yemen listed neither preparation for
artesunate. The Solomon Islands, in the WPRO region, listed all 3
antimalarials on its essential medicines list.
Procaine benzylpenicillin for pneumonia, although relatively
inexpensive and widely available, was listed on only about 50% of
the country lists in each region. Although the WHO recom-
mended formulation of oral rehydration salts was found on over
90% of lists globally, zinc sulfate was listed in only 30% of
countries in the AFRO region and less than 10% of countries in
the AMRO, EMRO, and WPRO regions.
Discussion
Millennium Development Goals 4 and 5 set targets for
reductions in child mortality and improvements in maternal
health and the UN Commission on Life-Saving Commodities for
Women and Children has noted that many of these deaths can be
prevented by access to basic medicines. Tracking progress towards
making life-saving medicines available for children and women is
needed to assess the attainment of these targets. National essential
medicines lists are key policy tools for promoting the supply of
priority medicines, especially through the public sector. Our
findings show that essential life-saving medicines for children and
mothers are not universally listed on national essential medicines
lists. Key medicines that would make a potential difference in
survival, such as zinc for diarrhoea in children or magnesium
sulfate for eclampsia in women, are not included consistently in
national documents. Many priority medicines are listed on less
Table 1. Priority Medicines for Mothers and Children.
Condition Chemical Entity Concentration and dosage form
Post-partum haemorrhage Oxytocin Injection 10 IU or 10 IU/ml
Misoprostol Tablet
Sodium chloride Injection
Sodium lactate (Ringer’s lactate) (Hartman’s) Injection
Severe pre-eclampsia and eclampsia Magnesium sulfate Injection 500 mg/ml or 50%
Calcium gluconate Injection 100 mg/ml or 10%
Maternal sepsis Ampicillin Injection
Gentamicin Injection
Metronidazole Injection 500 mg (or 5 mg/ml)
Sexually transmitted diseases Azithromycin At least one of the forms
Cefixime Capsule 400 mg (or tablet)
Benzathine benzylpenicillin Powder for injection
Pre-term birth Betamethasone or dexamethasone Injection
Nifedipine Capsules 10 mg (or tablet)
Pneumonia Amoxicillin Tablet (or capsule)
Ceftriaxone Powder for injection
Oxygen Medicinal gas
Procaine benzylpenicillin Injection
Diarrhoea ORS (oral rehydration salts) Sachet
Zinc Tablet 20 mg
Malaria Artemisinin combination therapy: artemether+lumefantrine or
artesunate+amodiaquine or dihydroartemisinin+piperaquine
Dispersible tablet or flexible oral solid dosage form
Artesunate Rectal
Artesunate Injection
Vitamin A deficiency Vitamin A (Retinol) Capsule
Neonatal sepsis Ceftriaxone Powder for injection
Gentamicin Injection
Procaine benzylpenicillin Injection
Palliative care Morphine At least one of the forms (granules, injection, oral
liquid, variable flexible oral solid dosage form)
Paracetamol Variable flexible oral dosage form (liquid,
suppository, tablet)
doi:10.1371/journal.pone.0038055.t001
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the listing of priority medicines because ‘‘missing’’ priority
medicines, such as a fixed dose combination product for pediatric
tuberculosis, were not assessed because they simply do not exist.
Countries need to urgently amend their lists to provide all priority
medicines as part of the efforts to achieve the targets for
Millennium Development Goals 4 and 5.
WHO supports countries in the selection of essential medicines
by publishing the Model Essential Medicines List. Since 2002,
biannual revisions of the WHO Model Essential Medicines List
have been rigorously evidence-based, and consider disease
prevalence, safety and efficacy of medicines [14]. Relative cost
may be evaluated as well, but no medicine is excluded from
consideration because of high cost [15]. The WHO advises
countries to adapt the Essential Medicines List according to their
priority health care needs [14]. The process for updating the
WHO Model list is transparent. Applications for deletions or
additions of medicines are reviewed by a WHO Expert
Committee.
The evidence provided in the applications, the committee
reviews, and the summary of the discussion and decisions are
publically available on the WHO website (http://www.who.int/
selection_medicines/committees/expert/18/en/index.html).
These publically available documents are a valuable resource for
countries seeking to develop or update their essential medicines
lists. Summaries and critical appraisals of the evidence reviewed by
the WHO Expert committee could be used by national medicine
selection committees to facilitate their own review processes.
Electronic reminders, linked to evidence summaries about newly
added medicines, could trigger the updating of national lists. In
addition, countries could benefit from WHO guidance in how to
create and operate medicines selection committees, including how
to evaluate evidence and manage conflicts of interest.
A limitation of our study is that we do not describe the reasons
why specific medicines are missing from specific national essential
medicines lists. To do so would require an in-depth country
analysis for each missing medicine because there are a variety of
possible reasons, which can vary by country and medicine, for the
lack of rapid policy change on national drug lists. However, our
findings are consistent with a number of possible reasons for gaps
in the listing of priority medicines for mothers and children on
essential medicines lists. The more up to date country lists were
more likely to contain the priority medicines. One exception was
nifedipine which until 2005 had been listed on the WHO Model
Figure 1. Percent of national Essential Medicines Lists (n=89) listing each Priority Medicine for Mothers and Children. Each bar
shows the percent of national Essential Medicines Lists (n=89) listing each Priority Medicine for Mothers and Children.
doi:10.1371/journal.pone.0038055.g001
Table 2. Listing on national essential medicines lists of four recently added to WHO Model List by date of list.
Medicine
Medicine listed
N( % )
Lists published prior to 2007 (n=24) Lists published in 2007 or later (n=65)
Misoprostol 5 (21%) 26 (40%)
Cefixime 3 (13%) 20 (31%)
Nifedipine 18 (75%) 39 (60%)
Zinc 1 (4%) 12 (18%)
doi:10.1371/journal.pone.0038055.t002
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in listing of this drug on the national lists may be due to its removal
for this cardiac indication and not reflect its addition as a tocolytic.
For some medicines, such as zinc sulfate, the desired quality
dispersible product is not widely manufactured. For children
under five, zinc supplementation significantly reduces the severity
and duration of diarrhea [16]. Although listing of zinc on the
Essential Medicines List can serve as an advocacy tool to create
demand for the product, some countries may hesitate listing a
product that is not widely available. The high proportion of
countries listing the low osmolarity oral rehydration salts suggests
that bundling or co-packaging of zinc with ORS could promote
uptake when a quality zinc product is available.
For other medicines, such as artesunate, a lack of demand may
be a barrier to inclusion on essential medicines lists. Artesunate
injection is difficult to obtain in the AFRO region compared to
SEARO. In addition, clinical practice guidelines lagged behind the
Model Essential Medicines List in recommending artesunate for
malaria in children. Artesunate was added to the Model List in
2000, but was not recommended as first line treatment for children
until 2011 (http://www.who.int/malaria/publications/atoz/
mal_treatchild_revised.pdf). The evidence supporting the use of
artesunate over quinine is recent and the latest WHO guidelines
have recommended either artesunate or quinine [12]. Countries
may have been hesitant to list artesunate when there was little
demand from practitioners.
In addition, local preferences and conditions can influence the
inclusion of medicines on country essential medicines lists. For
example, misoprostol was more likely to be listed on country
essential medicines lists in the WPRO region than any other
region. One reason for this may be that key opinion leaders in the
region argued for the inclusion of misoprostol because, unlike
oxytocin, it does not require refrigeration. The lack of cold storage
in the region may have convinced medicines selection committees
to add misoprostol.
Figure 2. Percent of national Essential Medicines Lists listing Priority Medicines for Mothers by WHO Region. Each bar shows the
percent of national Essential Medicines Lists listing Priority Medicines for Mothers by WHO Region. The abbreviations for the WHO regions are: AFRO
– Africa; AMRO – the Americas; EMRO – Eastern Mediterranean; EURO – Europe; SEARO – South-East Asia; WPRO – Western Pacific.
doi:10.1371/journal.pone.0038055.g002
Figure 3. Percent of national Essential Medicines Lists listing Priority Medicines for Children by WHO Region. Each figure shows the
percent of national Essential Medicines Lists listing Priority Medicines for Children by WHO Region. The 4 countries from Europe (the EURO region)
were excluded from this analysis as malaria and persistent diarrhea are not prevalent in this region. The abbreviations for the WHO regions are: AFRO
– Africa; AMRO – the Americas; EMRO – Eastern Mediterranean; SEARO – South-East Asia; WPRO – Western Pacific.
doi:10.1371/journal.pone.0038055.g003
Priority Medicines for Maternal and Child Health
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e38055Although listing on essential medicines lists is a first step in
making priority medicines available, there can be multiple
complex barriers to the use of essential medicines. Rapid country
assessments of barriers to the availability and use of priority
medicines are needed in order to design specific interventions to
increase their appropriate use. For example, although magnesium
sulfate is listed on the Essential Medicines List of Zambia, the
major barrier to availability within the public health system was
lack of procurement by the Ministry of Health [17]. Other barriers
identified included a lack of demand by health professionals at the
health center level and a lack of in-service training in the use of
magnesium sulfate. Where there was demand by obstetricians,
magnesium sulphate injection was being procured from the private
sector by the hospital pharmacy despite not being registered and
licensed for use for the treatment of severe pre-eclampsia and
eclampsia by the national Medicines Regulatory Authority.
In summary, this survey of priority medicines on national
essential medicines lists highlights the regional variability and poor
attention to life-saving priority medicines for children and
mothers. National pharmaceutical policies that include maintain-
ing an evidence-based and up-to-date essential medicines list can
be used to advocate for supply, procurement and proper use of
priority medicines. Ensuring that all national essential lists include
all the priority medicines would be potentially a quick win in
efforts to meet the targets specified in Millennium Development
Goals 4 and 5.
Supporting Information
Table S1 Priority medicines on country essential medicines lists
by country. Y=Yes, on list N=No, not on list.
(PDF)
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